Company Analysis

Vanda Pharmaceuticals Inc. (VNDA)

Nasdaq: VNDA · Pharmaceutical Preparations · Washington, DC · filing with the SEC since 2005
Grade6.0
◀ Past 7.4● Present 6.0▶ Future 4.5
1 est.

Who runs Vanda Pharmaceuticals Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Polymeropoulos Mihael Hristos
President and CEO. First filing Apr 2006, latest Mar 4, 2026, 29 filings in all.
Officers reporting now
8
of 14 people with a filing in the last fifteen months
Directors reporting now
6
23 people on the record since 2006
Officerssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Mcguire Daniel PatrickSVP, GC and SecretaryJun 2026Jun 8, 2026none
Howell Scott LaverneVP and Chief People OfficerApr 2026Apr 13, 2026none
Polymeropoulos Christos Vasilios MihaelSenior VP, Medical DirectorApr 2026Apr 13, 2026none
Polymeropoulos Mihael HristosPresident and CEOApr 2006Mar 4, 20261 · $1.3M
Moran Kevin PatrickSVP, CFO & TreasurerMar 2020Mar 4, 20261 · $400,000
Wijkstrom JoakimSVP, Chief Marketing OfficerAug 2019Mar 4, 20261 · $300,000
Birznieks GuntherSVP, Business DevelopmentMar 2017Mar 4, 20261 · $400,000
Williams TimothySVP & General CounselAug 2018Mar 4, 20261 · $400,000
Directorssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameRoleFirst filingLatest filingSales, 12 months
Duncan Charles CliffdirectorApr 2026Nov 5, 2026none
Chrousos PhaedradirectorApr 2019Jun 8, 2026none
Dugan Richard WdirectorApr 2006Jun 8, 2026none
Honore TagedirectorMar 2023Jun 8, 20261 · $200,000
Mitchell Stephen RaydirectorFeb 2020Jun 8, 2026none
Ward Anne SempowskidirectorOct 2019Jun 8, 2026none
Earlier names on the record15, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton VNDA · research, not advice